A new month means a new round-up of the top ten publications in the fields of AI and Real World Evidence, kindly collated by Benjamin Hughes, SVP at IQVIA.
Roche: Speculates that COVID-19 will accelerate the use of RWE in access and evidence/data based decision making.
Pfizer: On FDA oncology approvals (16-19), with 6 of 93 approvals levering RWE – 3 levered Flatiron data, one iKnowmed EMR, one EAP data, and one pooled RWD/RCT
Academia and industry published:
COVID mortality: HDRUK lever the UK Caliber (CPRD/HES) network to estimate risk factors and total UK excess mortality from COVID depending in different rates of Ro
US Department of Health and Human Services: On guidance of Clinical Decision Support (CDS) in EMR and the need to have full commercial separation from organizations such as pharma
COVID infection: PHE/Welcome lever the UK GP surveillance database to identify risks factors for COVID (e.g., male, older, black, urban, deprived, obese, non-smoker, CKD)
Real- world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy.
External controls: A primer for researchers on synthetic and external control arms in randomised clinical trials
COVID spread: AI model via modified auto-encoder (MAE) rather than SEIR model, estimating with late or limited intervention a potential 300m total cases and 9m global deaths
Fair Data: Various (FDA, NIH, EMA) combine with pharma to publish on the principles of FAIR data and the need for CDEs (Common data elements or models) in implementation
AI & firm performance: A review of 500 (non-healthcare) case studies and a reflection that AI can create immense value, but only if firms re-configure their business processes
Privacy by design: A team look at a variety of latest techniques, and also demonstration of a block-chain powered distributed analytics networks for IoT healthcare apps